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STATEMENT OF CLINICAL RELEVANCE
In this study, we aimed at getting further insight on the molecular characteristics differentiating tumor-associated stroma from normal stroma, and to investigate the potential clinical relevance of the breast stroma. We specifically concentrated on CD10+ cells since the most striking changes in gene expression were reported during breast cancer progression in this particular cell population from the breast cancer microenvironment (Allinen et al. Cancer Cell 2004) . We highlighted that this stroma contribution, defined by the CD10+ stroma signature, has a clinical relevance, particularly in patients with HER2+ tumors, where it is associated with worse prognosis and potentially to non-response to chemotherapy. We believe these results may help to better identify those patients for which the cancer stroma is, at least partly, responsible of their worse prognosis, and for which the stroma should thus be specifically targeted. Several studies have provided insight on the molecular characteristics differentiating tumor-associated stroma from normal stroma (1) (2) (3) (4) (5) . Allinen et al. were the first to perform systematic profiling of different stromal cell types isolated through celltype specific cell surface markers and magnetic beads (1) . Their work suggested that during cancer progression, striking changes in gene expression occurred in almost every cell type with the most dramatic and consistent changes (other than in the malignant epithelial cells) detected in cells which were characterized by the surface marker CD10, that encompasses myoepithelial cells and myofibroblasts. Later, two research groups have conducted exploratory global gene expression analysis of the tumor microenvironment using laser capture microdissected tumor and normal breast samples (2, 3) . Both publications reported important expression changes in genes related to the extracellular matrix in the cancer stroma compared to the normal stroma. Additionally, the study by Ma et al. also compared the epithelium and stromal compartment of ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) lesions: they observed no significant differences at the transcriptome level between the malignant epithelium of DCIS and IDC, whereas they found a significant number of genes differentiating DCIS and IDC lesions in the stromal compartment (2) .
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Very recently, Bauer et al. analyzed gene expression profiles from paired cancer associated and normal fibroblasts from 6 breast tumor specimen isolated through a method similar to the one developed by Allinen et al. (1) followed by short-term cell culture (4). They identified a list of 31 genes differentiating cancer associated from normal fibroblasts. Based on these genes and consistent with previous works, they suggest that the cancer associated fibroblasts contribute to cancer growth and progression by enhancing ECM production, promoting stromal-epithelial paracrine signaling and altering steroid hormone metabolism.
However the analysis of the clinical relevance of stroma-related molecular signatures has been relatively limited to date. Finak and colleagues identified a stromal signature (stroma-derived prognostic predictor, further referred to as SDPP) by comparing gene expression profiles of tumor stroma and matched normal stroma isolated by laser capture microdissection (LCM) from 53 primary breast tumors (5) . SDPP predicted outcome in several published whole tumor derived gene expression datasets, and especially in the HER2+ breast cancer subgroup. In parallel, using a prototype-based clustering approach, we developed a stroma-metagene (further referred to as PLAU) as a list of genes specifically correlated to PLAU, which was associated with prognosis only in the HER2+ breast cancer subgroup (6) . Using a similar approach, Farmer et al. defined their stromal metagene (further referred to as DCN) as a list of genes correlated to decorin; DCN was able to predict chemoresistance in patients treated with preoperative chemotherapy (7) .
In this paper, we aimed to gain further knowledge about the breast cancer stroma cellular compartment which according to Allinen et al. (1) 
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MATERIAL AND METHODS
Patients
Patients with invasive ductal breast carcinoma were recruited for the study at the Bordet Institute. Breast tissues were obtained at the time of the surgery. Since Finak et al.
demonstrated that stroma surrounding histologically normal ducts from tumor specimen and stroma isolated from reduction mammoplasties were highly similar at the gene expression level (8); we used histologically normal tissue distant from at least 2 cm from the tumor as normal breast tissue.
The study was approved by the ethics committee of the Bordet Institute. All patients included in this study signed the consent form.
Isolation of CD10+ cells
To isolate CD10+ cells from breast tissues, we established a procedure similar to the one described by Allinen et al. (1) and schematically illustrated in Supplementary Human Epcam selection kit, followed by a depletion of the CD45+ cells using the Human CD45 depletion kit from the same company. The CD10+ cells were further isolated from the unicellular suspension using human CD10+ selection kit. All selection kits were from STEMCELL technologies and were used according to the manufacturer's instructions.
The purity of the population was checked by flow cytometry (Antibodies CD326(Epcam) FITC from Milteny Biotec, APC anti human CD45 from Pharmingen and PE Mouse antihuman CD10 from Pharmingen).
Cell cultures
The 7 breast cancer cell lines MCF-7, T47D, LY2 (ER+/HER2-),MDA-MB-231, (ER-/HER2-), SKBR3, MDA-MB-361, BT474 (HER2+) and the CD10+ cell lines HS57BST (myoepithelial cells) and CRL2564 (fibroblasts) were obtained from the ATCC. They were cultured according to the media indicated by ATCC, except the HS57BST which we did not stimulate with EGF (Supplementary Table 1 ). Mesenchymal stem cells (MSCs) were isolated from bone marrow from a single female healthy donor and cultured as reported previously (9) .
For the co-culture experiments (each possible combination of a breast cancer cell line with a specific type of CD10+ cells), the CD10+ were first plated in petri dishes until sub-confluence. At that time the epithelial cells were added on top of the CD10+ cells.
After 4 days of co-culture, the CD10+ and epithelial cells were isolated using flow cytometry. The CD10+ cells used as control were not co-cultured with breast cancer cells. 
Gene expression data
We used the Human Genome U133-2.0 plus GeneChips to generate the gene expression data. More information about the experiments can be found in Supplementary methods.
Gene expression data were normalized by using the quantile normalization method of affy package version 1.28.0 (10) of the Bioconductor software project (http://www.bioconductor.org/). Subsequently data were log2 transformed. Microarray data are deposited in the Gene Expression Omnibus database under accession number GSE27120.
The CD10+ signature
To select the genes for the CD10+ signature, we carried out a class comparison of the tumor-associated CD10+ cells (n=28) with CD10+ cells from normal breast tissues (n=3) using the 10% most variant probesets across the entire series (n=5467 probesets).
The t-test was used to compare the mean values of probes across groups. To overcome the problem due to multiple testing, false discovery rate (FDR) (11) approach was used to select the top probesets. 
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We first selected those genes with an absolute fold change (FC) ≥ 1.5 and false discovery rate (FDR) < 0.05 for describing the genes differentially expressed and an absolute FC>4 and FDR<0.01 to generate the CD10+ signature respectively.
Using those genes, the CD10+ signature was computed for each sample as   The list of genes in the CD10+ stromal signature and the corresponding annotations have been submitted to GeneSigDB (12) .
Analysis of gene expression data
For the cell culture data, the Kruskal-Wallis test was applied to identify the differently expressed probes 1) between cell lines and 2) between the subtypes of each cell line. The Wilcoxon test was used to compute the differences between the different cell lines. It was not applied to the analyses within the different cell lines due to the too small number of samples for these comparisons. To overcome the problem due to multiple testing, false discovery rate (FDR) (11) 
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CD10+ stroma signature genes, except again for comparisons within the different cell lines due to the too small number of samples. The FC was calculated by the average difference between those groups.
To assess whether stromal genes can also be expressed in breast cancer epithelial cells, we examined the data from the invasive breast cancer cell lines from Neve et al. (13) . We first classified the cell lines according to the main 3 molecular subgroups of breast cancer: ER-/HER-, HER2+ and ER+/HER2-based on the ER and HER2 mRNA expression levels using the SCMGENE classifier as implanted in the genefu R package.
To evaluate the implication of the stromal genes in the transition from DCIS to invasive breast cancer, we used publicly available gene expression data from matched DCIS/invasive cancer (14) .
To investigate the prognostic value of the CD10+ stroma signature, gene expression datasets were retrieved from public databases or authors' websites. We used normalized data (log2 intensity in single-channel platforms or log2 ratio in dual-channel platforms) as published by the original studies. Hybridization probes were mapped to Entrez GeneID as described (15), using RefSeq and Entrez database version 2007.01. 21 .
When multiple probes were mapped to the same GeneID, the one with the highest variance in a particular dataset was selected. Seven public breast cancer microarray datasets were used (16) (17) (18) (19) (20) (21) (22) (23) (24) Supplementary 14 survival (RFS). We censored the survival data at 10 years in order to have comparable follow-up across the different studies as described (6, 16, 25) . The hazard ratio (HR) was estimated for each dataset separately and combined with inverse variance-weighted method (26) .The Kaplan-Meier product-limit estimator was used to display time to event curves. The tertiles for the signature scores were computed within each breast cancer molecular subtypes separately, in order to estimate the signature's prognostic value for each subtype.
To investigate the prognostic value of the CD10+ stroma signature when treating patients with anthracycline-based chemotherapy, we used gene expression data treated in the TOP trial, NCT00162812 (27) . In this trial, patients with estrogen receptor (ER)-negative tumors were treated with anthracycline (epirubicin) monotherapy, allowing investigating anthracycline-specific predictors. The area under the curve (AUC) and its confidence interval was estimated through the concordance index (28) , and its one-sided p-value was determined by the Wilcoxon Rank Sum test.
All the analysis were performed using R software version 2.9.2 (www.r-project.org)
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RESULTS
Development of the CD10+ stroma signature
Using an approach similar to that of Allinen et al. (1), we were able to isolate tumor-associated CD10+ cells (n=28) as well as CD10+ samples from normal breast tissues (n=3). The characteristics of the tumors are illustrated in Table 1 Supplementary Table 4) . We computed the gene overlap between this list and the various published signatures (see Supplementary Table   5 ). All signatures showed some gene overlap except SDPP. COL10A1, the gene which in our dataset was the most differentially expressed between tumor and normal CD10+ cells was present in all signatures, except PLAU and SDPP.
To develop a signature we selected from the above reported comparison the most differentially expressed genes, with |FC| ≥ 4 and FDR < 0.01 (Supplementary Table 6 ).
Twelve genes were selected based on these criteria. The reason we developed a signature based on a small number of genes was to facilitate its potential future translation into clinic by evaluating a small number of genes using an RT-PCR assay for instance. Table 7 ). This confirms that the variability of these specific genes is higher in tumor-associated CD10+ compared to normal CD10+ cells.
Characterization of the CD10+ stroma signature
In order to investigate whether our CD10+ stroma signature genes were exclusively expressed in stromal cells, we examined their expression levels in the breast cancer cell line dataset made available by Neve et al. (13) . We observed that for half of Of note, no significant differences in cell proliferation were noticed in the co-culture experiments, except that the ER+/HER2-breast cancer cell lines were more proliferative after co-culture with fibroblasts than were the other breast cancer cell lines co-cultured with fibroblasts (Supplementary Figure 4) .
Clinical relevance of the CD10+ stroma signature
Since it has repeatedly been suggested that the progression of DCIS to invasive breast cancer could be strongly dependent upon changes in the stroma (reviewed in 29), we aimed at investigating whether our CD10+ stroma signature was able to differentiate 
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DCIS samples from their associated invasive counterparts. To this end, we used publicly available gene expression data from DCIS and their associated invasive counterparts isolated by laser capture microdissection (LCM) (14) .
Interestingly, as illustrated in Figure 3 , our CD10+ stroma signature was able to differentiate DCIS from invasive cancer. This figure also illustrates the different expression levels of the signature genes in DCIS and IDC.
Recently, three studies have investigated the clinical relevance of global gene expression signatures describing the stromal compartment in invasive breast cancer (5-7) using gene expression data generated from whole breast tumor tissue comprising both tumor epithelium and stroma.To assess whether our CD10+ stromal signature could predict outcome from such data, we analyzed available microarray data generated from whole tumors of 1,140 patients who did not receive any systemic treatment (16) (17) (18) (19) (20) (21) (22) (23) (24) . Table 12 ). The Kaplan-Meier curves are illustrated in Figure 4 . In agreement with previous reports, SDPP, PLAU and DCN also carried prognostic information in this same HER2+ population (Supplementary Table 12 We further wanted to evaluate whether our stroma signature was correlated with response/resistance to chemotherapy or whether it was just associated with the natural history of the disease. Collagens, which are part of the transport barrier imposed by the ECM and also part of our signature (COL10A1 and COL11A1), have been demonstrated to be, at least partly, responsible for decreased penetration of therapeutic agents in the tumor (30) . We therefore investigated the association of our CD10+ signature with the pathological complete response (pCR) status in the well-defined prospective TOP trial (27) . Patients in this dataset had estrogen-receptor negative tumors and were treated with pre-operative epirubicin only. Similarly to the above results, we observed that the CD10+ stroma signature was only significantly associated with lack of pCR in patients with HER2+ tumors (Figure 5 ). Consistent with the fact that our signature was correlated with PLAU and DCN, these two signatures also were associated with pCR in this subgroup of patients, but not SDPP (Supplementary Table 14) . However, these results should be interpreted with caution given the small number of patients in this HER2+ subgroup (n=30). 
DISCUSSION
In this paper, we compared gene expression profiles from tumor-associated CD10+ cells with CD10+ cells from normal breast tissue. Our hypothesis was that by selecting only CD10+ cells we investigated a more uniform stromal compartment at the cellular level compared to previous publications which used LCM to dissect the stroma fraction and which thus considered the stroma as a uniform entity (2, 3, 5) . Of note, the recent publication of Bauer et al. (4) used a similar approach as the one we used, except that they subjected the isolated cells to short term culture, with the potential disadvantage that it could mask some of the originally existing differences in gene expression, and that they did not investigate their potential clinical relevance.
As in previous descriptive studies, we found many genes associated with the remodeling of the extracellular matrix, such as matrix metalloproteases, collagens and fibronectin. Interestingly, we also observed a certain number of genes linked with skeletal development such as periostin (POSTN). It has been shown that POSTN is undetectable in normal breast tissues, whereas elevated levels are observed in breast cancer tumor samples. It has also been demonstrated that serum POSTN levels are elevated in breast cancer patients with bone metastases from breast cancer (reviewed in 31). Another recent report showed, using a well-defined animal model, that bone metastases from breast cancer are associated with a marked overexpression of this stroma-derived POSTN (32) .
From the comparison between tumor and normal CD10+ cells, we selected those genes with the highest FC and lowest corrected p-value to develop the CD10+ stroma signature. To assess whether the genes included in this signature could also be expressed MSCs, we performed cell line co-culture experiments to understand the contribution of each cell type. Although the cell culture results should be taken with caution since these co-culture experiments are just an artificial representation of these CD10+/breast cancer epithelial cells interaction, three main messages could be derived from the cell culture analyses. First, by comparing the CD10+ stroma signature scores between the three CD10+ cell types, we observed that the highest signature scores were observed in MSCs followed by the fibroblasts. We further also observed changes in the signature score within each cell type following co-culture with breast cancer cells. Second, by comparing the expression levels of the different CD10+ stroma signature genes between the three CD10+ cell types, it clearly appears that all three cell types contribute to the CD10+ stroma signature. Indeed, some genes are more highly expressed both in fibroblasts and MSCs (POSTN and ADH1B), whereas other genes are more expressed in myoepithelial cells only (such as GJB2, PCOLCE2 and HSD17B6) or MSCs only (MMP13 and COL10A1). Third, by investigating the expression levels of the different CD10+ stroma signature genes within each CD10+ cell type, we observed that the expression of some genes clearly differed in some co-culture conditions compared to controls: MMP13 for the fibroblasts, HSD17B6 and POSTN for the MSCs, and GJB2, MATN3 and HSD17B6
for the myoepithelial cells. 
24
We further aimed to investigate the clinical relevance of our CD10+ stroma signature. We first demonstrated that our signature and the majority of its genes were able to discriminate DCIS from associated invasive samples. This finding confirms previous findings that suggested that progression from in situ to invasive breast cancer may not be due to the changes in the epithelial cells but dependent upon the tumor microenvironment (33) (34) (35) .
Using gene expression data generated from whole tumor tissue, we further demonstrated that our CD10+ stromal signature carried prognostic value in the HER2+ breast cancer population of untreated breast cancer patients only. We observed similar results for the previously developed stroma signatures, the PLAU module and SDPP (6, 7) . A moderate but significant correlation was observed between our CD10+ stroma signature and the PLAU module, although these were generated using a completely different approach (CD10+cells isolation versus in silico development using whole tumor tissue gene expression data). On the contrary, no correlation was observed between our signature and SDPP although both were developed from the comparison of tumor versus normal stroma. One possible reason for this is that the authors from SDPP isolated the stroma using LCM and therefore most probably considered additional cell types. Why would this stroma signature be particularly relevant in HER2+ breast cancer? In these HER2+ cancers, the activity of HER2 can be due to its transactivation. Cabioglu et al recently suggested a novel mechanism of HER2 transactivation through CXCL12/SDF1 stimulation of the CXC4R4 chemokine receptor, and this only in breast cancer cells that express high levels of HER2 (36). In our cell line data, we observed that MSCs and 
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especially fibroblasts co-cultured with HER2+ breast cancer cells express very high levels of CXCL12 (data not shown). Alternatively, POSTN could be playing a role in breast cancer progression of HER2+ breast cancer since increased expression has been correlated with a worse prognosis (32) and since we observed the highest levels of POSTN in our cell culture experiments in MSCs after co-culture with HER2+ breast cancer cells. However, the exact tumor-epithelium interactions explaining the specific clinical relevance of the stroma in HER2+ breast cancer still need to be investigated and will be the focus of future research.
We recognize the limitation of our study, i.e. the under-representation of the different molecular subgroups of breast cancer in the tumor population used for CD10+ isolation. However, to our knowledge, this is the first study which isolates a specific cellular stromal compartment, in contrast to the majority of the previous studies which used LCM, analysed extensively its clinical value and further characterized it by coculture experiments.
To conclude, we believe that the comprehensive characterization of this welldefined stroma compartment reinforces the importance of tumor epithelial-stroma cell interactions in tumorigenesis. We highlighted that this stroma contribution, defined by the All ER-samples All ER-/HER2-samples All ER-/HER2+ samples
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